Get startedLog in
    Picture of Antibe Therapeutics(Pre-Merger) logo

    ATE — Antibe Therapeutics(Pre-Merger) Cashflow Statement

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Antibe Therapeutics(Pre-Merger), fiscal year end - March 31st, CAD millions except per share, conversion factor applied.

    2019
    March 31st
    R2020
    March 31st
    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-12.8-19.1-24.7-25.3-19.3
    Depreciation
    Amortisation
    Deferred Taxes
    Non-Cash Items4.435.124.485.582.95
    Discontinued Operations
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital0.9112.0119.72.65-0.228
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-7.06-11.3-0.105-16.9-16.3
    Capital Expenditures-0.157-0.001—-0.009-0.009
    Purchase of Fixed Assets
    Other Investing Cash Flow Items-0.1-0.46-0.264-20.2-11.8
    Acquisition of Business
    Sale of Fixed Assets
    Change in Net Investments
    Purchase of Investments
    Change in Net Intangibles
    Other Investing Cash Flow
    Cash from Investing Activities-0.257-0.461-0.264-20.2-11.8
    Financing Cash Flow Items-0.845-0.933-5.61-0.0020.159
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities9.591266.2-0.0260.08
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash2.270.19365.8-37.2-28.1